Skip to main content
SpringerLink
Log in
Book cover

Multimodal Concepts for Integration of Cytotoxic Drugs pp 231–250Cite as

Applications in Lung Cancer

  • Chapter

  • 559 Accesses

Part of the Medical Radiology book series (Med Radiol Radiat Oncol)

Keywords

  • Clin Oncol
  • Small Cell Lung Cancer
  • Radiat Oncol Biol Phys
  • Radiation Therapy Oncology Group
  • Concurrent Radiochemotherapy

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   189.00
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (Canada)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   249.99
Price excludes VAT (Canada)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Albain KS, Rusch VW, Crowley JJ et al (1995) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: major mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880–1892

    PubMed  CAS  Google Scholar 

  • Albain KS, Crowley JJ, Turrisi AT et al (2002) Concurrent cisplatin, etoposide plus radiotherapy for pathologic stage IIIB non-small cell lung cancer: a Southwest Oncology Group phase II study (S9019). J Clin Oncol 20:3454–3460

    CrossRef  PubMed  CAS  Google Scholar 

  • Albain KS, Swann RS, Rusch VW et al (2005) Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small-cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol ASCO Annual Meeting Proceedings 23(16S):LBA7014

    Google Scholar 

  • Andre F, Grunenwald D, Pignon JP et al (2000) Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18:2981–2989

    PubMed  CAS  Google Scholar 

  • Arriagada R, Kramar A, Le Chevalier T et al (1992) Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers’ Lung Group. J Clin Oncol 10:447–451

    PubMed  CAS  Google Scholar 

  • Arriagada R, Bergman B, Dunant A et al (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350:351–360

    CrossRef  PubMed  Google Scholar 

  • Baumann M, Herrmann T et al (1997) CHARTWEL-Bronchus (ARO 97-1): a randomized multicenter trial to compare conventional fractionated radiotherapy with CHARTWEL radiotherapy in inoperable non-small-cell bronchial carcinoma. Strahlenther Onkol 173:663–667

    CrossRef  PubMed  CAS  Google Scholar 

  • Baumann M, Herrmann T, Koch R et al (2005) Continuous hyperfractionated accelerated radiotherapy: weekend less (CHARTWEL) versus conventionally fractionated (CF) radiotherapy in non-small-cell lung cancer (NSCLC): first results of a phase III randomised multicentre trial (ARO 971). Eur J Cancer 3(Suppl):322

    Google Scholar 

  • Bonner J, Sloan J, Shanahan T et al (1999) Phase III comparison of twice daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 17:2681–2691

    PubMed  CAS  Google Scholar 

  • Bradley J (2005) A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. Semin Oncol 32(2 Suppl 3):111–113

    CrossRef  Google Scholar 

  • Bradley J, Graham MV, Winter K et al (2005) Toxicity and outcome results of RTOG 9311: a phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61:318–328

    CrossRef  PubMed  Google Scholar 

  • Brodin O, Lennartsson L, Nilsson S (1991) Single-dose and fractionated irradiation of four human lung cancer cell lines in vitro. Acta Oncol 30:967–974

    PubMed  CAS  Google Scholar 

  • Carmichael J, Degraff WG, Gamson J et al (1989) Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol 25:527–534

    CrossRef  PubMed  CAS  Google Scholar 

  • Choi N, Carey RW, Daly W et al (1997) Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 15:712–722

    PubMed  CAS  Google Scholar 

  • Choy H, Curran WJ, Scott CB et al (2002) Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized 3-arm phase II study of three chemoradiation regimens with paclitaxel, carboplatin and thoracic radiation (TRT) for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol 2002:1160

    Google Scholar 

  • Chute JP, Venzon DJ, Hankins L et al (1997) Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 72:901–912

    CrossRef  PubMed  CAS  Google Scholar 

  • Clamon G, Herndon J, Cooper R et al (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17:4–11

    PubMed  CAS  Google Scholar 

  • Cullen MH, Billingham LG, Woodroffe CM et al (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol 17:3188–3194

    PubMed  CAS  Google Scholar 

  • Curran WJ, Scott CB, Langer C et al (2000) Phase III comparison of sequential versus concurrent chemo-radiation for patients with unresected stage III non-small-cell lung cancer: initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000:1891

    Google Scholar 

  • Curran WJ, Scott CT, Langer C et al (2003) Long-term benefit is observed in phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003:2499

    Google Scholar 

  • Depierre A, Milleron B, Moro-Sibilot D et al (2002) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20:247–253

    CrossRef  PubMed  Google Scholar 

  • De Ruysscher D, Wanders S, van Haren E et al (2005a) Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 62:988–994

    CrossRef  PubMed  Google Scholar 

  • De Ruysscher D, Wanders S, Minken A et al (2005b) Effects of radiotherapy planning with a dedicated combined PETCT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose escalation: a planning study. Radiother Oncol 77:5–10

    CrossRef  PubMed  Google Scholar 

  • Dillman RO, Herndon J, Eaton WL et al (1996) Improved survival in stage III non-small-cell lung cancer: seven year follow up of Cancer and Leukaemia Group B 8433 trial. J Natl Cancer Inst 88:1210–1215

    PubMed  CAS  Google Scholar 

  • Douillard J, Rosell R, Delena M et al (2005) ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I–III) non-smallcell lung cancer (NSCLC) patients: final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. J Clin Oncol ASCO Annual Meeting Proceedings 23(16S):LBA7013

    Google Scholar 

  • Duchesne GM, Peacock JH, Steel GG (1986) The acute in vitro and in vivo radiosensitivity of human lung tumor lines. Radiother Oncol 7:353–361

    PubMed  CAS  Google Scholar 

  • Eberhardt W, Wilke H, Stamatis G et al (1998) Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-smallcell lung cancer: mature results of a phase II trial. J Clin Oncol 16:622–634

    PubMed  CAS  Google Scholar 

  • Emami B (1996) Three-dimensional conformal radiation therapy in bronchogenic carcinoma. Semin Radiat Oncol 6:92–97

    CrossRef  PubMed  Google Scholar 

  • Erridge S, Murray N (2003) Thoracic radiotherapy for limited-stage small cell lung cancer: issues of timing, volumes, dose, and fractionation. Semin Oncol 30:26–37

    CrossRef  PubMed  Google Scholar 

  • Fossella FV, Tolcher A, Elliott M et al (2002) Phase I trial of the monoclonal antibody conjugate, BB-10901, for relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine tumors. Proc Am Soc Clin Oncol 21:309a (abstr 1232)

    Google Scholar 

  • Fournel P, Robinet G, Thomas P et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cel lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23:5910–5917

    CrossRef  PubMed  CAS  Google Scholar 

  • Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246

    CrossRef  PubMed  CAS  Google Scholar 

  • Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699

    PubMed  CAS  Google Scholar 

  • Gandara D, Chansky K, Albain KS et al (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004–2010

    CrossRef  PubMed  CAS  Google Scholar 

  • Giaccone G, Herbst RS, Manegold C et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22:777–784

    CrossRef  PubMed  CAS  Google Scholar 

  • Gridelli C, Rossi A, Maione P (2003) Treatment of non-smallcell lung cancer: state of the art and development of new biologic agents. Oncogene 22:6629–6638

    CrossRef  PubMed  CAS  Google Scholar 

  • Grunenwald D, Andre F, Le Pechoux C et al (2001) Benefit of surgery after chemo-/ radiotherapy in stage IIIB (T4 and / or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 122:796–802

    CrossRef  PubMed  CAS  Google Scholar 

  • Hahn SM, Bernhard E, Regine W et al (2002) A phase I trial of the farnesyltransferase inhibitor L-778, 123 and radiotherapy for locally advanced lung and head and neck. Clin Cancer Res 8:1065–1072

    PubMed  CAS  Google Scholar 

  • Hellwig D, Graeter TP, Ukena D et al (2004) Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. Thorac Cardiovasc Surg 128:892–899

    CrossRef  Google Scholar 

  • Herbst RS, Giaccone G, Schiller JH et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial — INTACT 2. J Clin Oncol 22:785–794

    CrossRef  PubMed  CAS  Google Scholar 

  • Huber RM, Schmidt M, Flentje M et al (2003) Induction chemotherapy and following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (stage IIIA/IIIB). Proc Am Soc Clin Oncol 2003:2501

    Google Scholar 

  • Jeremic B, Shibamoto Y, Acimovic L et al (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage-III nonsmall-cell lung cancer: a randomized study. J Clin Oncol 14:1065–1070

    PubMed  CAS  Google Scholar 

  • Jeremic B, Shibamoto Y, Acimovic L et al (1997) Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 15:893–900

    PubMed  CAS  Google Scholar 

  • Johnson BE, Fisher B, Fisher T et al (2002) Phase II study of STI571 (gleevec) for patients with small-cell lung cancer. Proc Am Soc Clin Oncol 21:293a (Abstract 1171)

    Google Scholar 

  • Keller SM, Sudeshna A, Wagner H et al (2000) A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 343:1217–1222

    CrossRef  PubMed  CAS  Google Scholar 

  • Kies MS, Mira JG, Crowley JJ et al (1987) Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with widefield versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol 5:592–600

    PubMed  CAS  Google Scholar 

  • Komaki R, Swann S, Ettinger D et al (2005) Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 62:342–350

    CrossRef  PubMed  CAS  Google Scholar 

  • Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 290:2149–2158

    CrossRef  CAS  Google Scholar 

  • Le Chevalier T, Arriagada R, Quoix E et al (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417–423

    PubMed  Google Scholar 

  • Le Chevalier T, Brisgard D, Douillard JY et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 14:360–367

    Google Scholar 

  • Lee D, Han JY, Kwan H et al (2005) Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 63:1037–1044

    CrossRef  PubMed  CAS  Google Scholar 

  • Lilenbaum R et al (2005) A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): final results. J Clin Oncol ASCO Annual Meeting Proceedings 23(16S):LBA7036

    Google Scholar 

  • Lu C, Komaki R, Herbst RS et al (2003) A phase III study of AE-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim overall toxicity report. Proc Am Soc Clin Oncol 2003:2665

    Google Scholar 

  • Marino P, Preatoni A, Cantoni A et al (1997) Randomized trials of radiotherapy alone vs combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer: a meta-analysis. J Clin Oncol 15:2996–3018

    Google Scholar 

  • Mascaux C, Paesmans M, Berghmans T et al (2000) A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30:23–26

    CrossRef  PubMed  CAS  Google Scholar 

  • Milas L, Kishi K, Hunter N et al (1999) Enhancement of tumor response to gamma-irradiation by an inhibitor of cyclo-oxygenase-2 enzyme. J Natl Cancer Inst 91:1501–1504

    CrossRef  PubMed  CAS  Google Scholar 

  • Murray N, Coy P, Pater JL et al (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Institute of Canada Clinical Trials Group. J Clin Oncol 11:336–344

    PubMed  CAS  Google Scholar 

  • Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91

    CrossRef  PubMed  CAS  Google Scholar 

  • Pass HI, Pogrebniak HW, Steinberg SM et al (1992) Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 53:992–998

    CrossRef  PubMed  CAS  Google Scholar 

  • Perez CA, Stanley K, Rubin P et al (1980) A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung: preliminary report by the Radiation Therapy Oncology Group. Cancer 45:2744–2753

    CrossRef  PubMed  CAS  Google Scholar 

  • Perry MC, Eaton WL, Propert KJ et al (1987) Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316:912–918

    CrossRef  PubMed  CAS  Google Scholar 

  • Perry MC, Herndon JE III, Eaton WL et al (1998) Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B study 8083. J Clin Oncol 16:2466–2469

    PubMed  CAS  Google Scholar 

  • Petersen C, Petersen S, Milas L et al (2000) Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 6:2513–2520

    PubMed  CAS  Google Scholar 

  • Pignon JP, Arriagada R, Ihde DC et al (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618–1627

    CrossRef  PubMed  CAS  Google Scholar 

  • Pritchard RS, Anthony SP et al (1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer: a meta-analysis. Ann Intern Med 125:723–729

    PubMed  CAS  Google Scholar 

  • Pujol JL, Carestia L, Daures JP (2000) Is there a case for cisplatin in the treatment of small-cell lung cancer? A metaanalysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83:8–15

    CrossRef  PubMed  CAS  Google Scholar 

  • Pyo H, Choy H, Amorino GP et al (2001) A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7:2998–3005

    PubMed  CAS  Google Scholar 

  • Rakovitch E, Tsao M, Ung Y et al (2004) Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys 58:196–203

    CrossRef  PubMed  Google Scholar 

  • Rapp E, Pater JL, Willan A et al (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer. Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633–641

    PubMed  CAS  Google Scholar 

  • Robinson L, Wagner H, Ruckdeschel J (2003) Treatment of stage III A non-small cell lung cancer. Chest 123:202S–220S

    CrossRef  PubMed  Google Scholar 

  • Rosell R, Gomez-Codina J, Camps C et al (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153–158

    CrossRef  PubMed  CAS  Google Scholar 

  • Rosell R, Gomez-Codina J, Camps C et al (1999) Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 26:7–14

    CrossRef  PubMed  CAS  Google Scholar 

  • Rosell R et al (2005) Pr3 ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I–III) non small cell lung cancer (NSCLC) patients. Lung Cancer 49(S2):S3–S4

    CrossRef  Google Scholar 

  • Roth JA, Fossella F, Komaki R (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86:673–680

    PubMed  CAS  Google Scholar 

  • Roth JA, Atkinson EN, Fossella F et al (1998) Long-term followup of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21:1–6

    CrossRef  PubMed  CAS  Google Scholar 

  • Ruckdeschel JC (1997) Combined modality treatment of nonsmall cell lung cancer. Semin Oncol 24:429–439

    PubMed  CAS  Google Scholar 

  • Salomon DS, Brandt R, Ciardello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232

    PubMed  CAS  Google Scholar 

  • Saunders M, Dische S, Barrett A et al (1997) Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 350:161–165

    CrossRef  PubMed  CAS  Google Scholar 

  • Sause W, Kolesar P, Taylor S et al (2000) Final results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group and Southwest Oncology Group. Chest 117:358–364

    CrossRef  PubMed  CAS  Google Scholar 

  • Scagliotti V, Fossati R, Torri V et al (2003) Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small-cell lung cancer. J Natl Cancer Inst 95:1453–1461

    PubMed  CAS  Google Scholar 

  • Schaake-Koning C, van den Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524–530

    CrossRef  PubMed  CAS  Google Scholar 

  • Sheperd F, Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    CrossRef  Google Scholar 

  • Simon G, Ginsberg RJ, Ruckdeschel JC (2001) Small-cell lung cancer. Chest Surg Clin N Am 11:165–188

    PubMed  CAS  Google Scholar 

  • Skarlos DV, Samantas E, Kosmidis P et al (1994) Randomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol 5:601–607

    PubMed  CAS  Google Scholar 

  • Skarlos DV, Samantas E, Briassoulis E et al (2001) Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Group (HeCOG). Ann Oncol 12:1231–1238

    CrossRef  PubMed  CAS  Google Scholar 

  • Stewart LA (1995) The Non-small Cell Lung Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899–909

    Google Scholar 

  • Stuschke M, Pöttgen C (2004) Lunge und Mediastinum. In: Bamberg M, Molls M, Sack H (eds) Radioonkologie Klinik. W. Zuckerschwerdt Verlag, München Wien New York, pp 882–885

    Google Scholar 

  • Sundstrom S, Bremnes RM, Kaasa S et al (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristin regimen in small-cell lung cancer: results of a randomized phase III trial with 5 years followup. J Clin Oncol 20:4665–4672

    CrossRef  PubMed  CAS  Google Scholar 

  • Takada M, Fukuoka M, Kawahara M et al (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group study 9104. J Clin Oncol 20:3054–3060

    CrossRef  PubMed  CAS  Google Scholar 

  • Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537

    CrossRef  PubMed  CAS  Google Scholar 

  • Thomas M, Rübe C, Semik M et al (1999) Chemotherapy and subsequent twice-daily chemoradiation before surgery in stage III non-small cell lung cancer: impact of tumor regression on survival. J Clin Oncol 17:1185–1193

    PubMed  CAS  Google Scholar 

  • Thomas M et al (2004) Cisplatin/etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): a randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG). J Clin Oncol ASCO Annual Meeting Proceedings 22(14S):7004

    Google Scholar 

  • Turrisi A, Kyungmann K, Blum R et al (1999) Twice-daily compared with once daily thoracic radiotherapy in limited small-cell-lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265–271

    CrossRef  PubMed  CAS  Google Scholar 

  • Van Meerbeeck JP, Kramer G, Van Schil PE et al (2005) A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction therapy (ICT) (EORTC 08941). J Clin Oncol ASCO Annual Meeting Proceedings 23(16S):LBA7015

    Google Scholar 

  • Vansteenkiste JF, De Leyn PR, Deneffe GJ et al (1998) Clinical prognostic factors in surgically treated stage IIIAN2 non small cell lung cancer: analysis of the literature. Lung Cancer 19:3–13

    CrossRef  PubMed  CAS  Google Scholar 

  • Vokes EE, Choy H (2003) Targeted therapies for stage III nonsmall cell lung cancer: integration in the combined modality setting. Lung Cancer 41:S115–S121

    CrossRef  PubMed  Google Scholar 

  • Vokes EE et al (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer. Cancer and Leukemia Group B Study 9431. J Clin Oncol 20:4191–4198

    CrossRef  PubMed  CAS  Google Scholar 

  • Vokes EE, Herndon JE, Kelley MJ et al (2004) Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): intial analysis of randomized phase III trial. J Clin Oncol 14(S):7005

    Google Scholar 

  • Wang WL, Healy ME, Sattler M et al (2000) Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by novel tyrosine kinase inhibitor STI 571. Oncogene 19:3521–3528

    CrossRef  PubMed  CAS  Google Scholar 

  • Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890–895

    PubMed  CAS  Google Scholar 

  • Werner-Wasik M et al (2005) A phase II study of cetuximab (C225) in combination with chemoradiation in patients with stage IIIA/B non-small cell lung cancer: an interim overall toxicity report of the RTOG 0324 trial. J Clin Oncol ASCO Annual Meeting Proceedings 23(16S):LBA7135

    Google Scholar 

  • Work E, Nielsen OS, Bentzen SM et al (1997) Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol 15:3030–3037

    PubMed  CAS  Google Scholar 

  • Zatloukal P, Petruzelka L, Zemanova M et al (2000) Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study. Proc Am Soc Clin Oncol 2000:1976

    Google Scholar 

  • Zemanova M, Petruzelka L, Havel L et al (2002) Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study. Proc Am Soc Clin Oncol 2002:1159

    Google Scholar 

  • Zips D, Baumann M (2003) Anti-VEGF strategies in combination with radiotherapy. In: Nieder C, Milas L, Ang K (eds) Modification of radiation response. Springer, Berlin Heidelberg New York, pp 179–188

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiotherapy and Radiation Oncology, Saarland University Medical School, 66421, Homburg, Germany

    Jochen Fleckenstein MD

  2. Department of Radiotherapy and Radiation Oncology, Saarland University Medical School, 66421, Homburg, Germany

    Christian Rübe MD, PhD (Head)

Authors
  1. Jochen Fleckenstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Rübe MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford School of Medicine, 269 Campus Drive Center for Clinical Science and Research, Rm 1255, Stanford, CA, 94305-5152, USA

    J. Martin Brown PhD

  2. Department of Human Oncology, University of Wisconsin Hospital Medical School, 600 Highland Ave., K4 312-3684, Madison, WI, 53792, USA

    Minesh P. Mehta MD

  3. Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Strasse 22, 81675, München, Germany

    Carsten Nieder MD

Rights and permissions

Reprints and Permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fleckenstein, J., Rübe, C. (2006). Applications in Lung Cancer. In: Brown, J.M., Mehta, M.P., Nieder, C. (eds) Multimodal Concepts for Integration of Cytotoxic Drugs. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-35662-2_16

Download citation

  • DOI: https://doi.org/10.1007/3-540-35662-2_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-25655-7

  • Online ISBN: 978-3-540-35662-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

search

Navigation